Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Stauffer Larsen, T, Iversen, KF, Hansen, E, Mathiasen, AB, Marcher, CW, Frederiksen, MB, Larsen, H, Helleberg, I, Riley, CH, Bjerrum, OW, Rønnov-Jessen, D, Møller, MB, de Stricker, K, Vestergaard, H & Hasselbalch, HC 2013, 'Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha' Leukemia Research, bind 37, nr. 9, s. 1041-5. https://doi.org/10.1016/j.leukres.2013.06.012

APA

CBE

Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher CW, Frederiksen MB, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC. 2013. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research. 37(9):1041-5. https://doi.org/10.1016/j.leukres.2013.06.012

MLA

Vancouver

Author

Stauffer Larsen, Thomas ; Iversen, Katrine F ; Hansen, Esben ; Mathiasen, Anders Bruun ; Marcher, Claus Werenberg ; Frederiksen, Mikael Brink ; Larsen, Herdis ; Helleberg, Inge ; Riley, Caroline Hasselbalch ; Bjerrum, Ole W ; Rønnov-Jessen, Dorthe ; Møller, Michael Boe ; de Stricker, Karin ; Vestergaard, Hanne ; Hasselbalch, Hans Carl. / Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. I: Leukemia Research. 2013 ; Bind 37, Nr. 9. s. 1041-5.

Bibtex

@article{bf2e17c4b6154429922fcae62d38ab2a,
title = "Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha",
abstract = "Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95{\%}, PV 68{\%}) and molecular response. In total 76 patients (74.5{\%}) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59{\%} (95{\%} c.i. 50-73{\%}, range 3-99{\%}). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10{\%} (95{\%} c.i.: 8-16{\%}), and PV (median 59-35{\%} (95{\%} c.i.: 17-33{\%}). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10{\%}) had deep molecular remissions with ≤ 2{\%} JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.",
keywords = "Adolescent, Adult, Aged, Denmark, Female, Follow-Up Studies, Humans, Interferon-alpha, Janus Kinase 2, Male, Middle Aged, Mutation, Polycythemia Vera, Primary Myelofibrosis, Prognosis, Recombinant Proteins, Remission Induction, Retrospective Studies, Thrombocythemia, Essential, Time Factors, Young Adult",
author = "{Stauffer Larsen}, Thomas and Iversen, {Katrine F} and Esben Hansen and Mathiasen, {Anders Bruun} and Marcher, {Claus Werenberg} and Frederiksen, {Mikael Brink} and Herdis Larsen and Inge Helleberg and Riley, {Caroline Hasselbalch} and Bjerrum, {Ole W} and Dorthe R{\o}nnov-Jessen and M{\o}ller, {Michael Boe} and {de Stricker}, Karin and Hanne Vestergaard and Hasselbalch, {Hans Carl}",
note = "Copyright {\circledC} 2013 Elsevier Ltd. All rights reserved.",
year = "2013",
month = "9",
doi = "10.1016/j.leukres.2013.06.012",
language = "English",
volume = "37",
pages = "1041--5",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Pergamon",
number = "9",

}

RIS

TY - JOUR

T1 - Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha

AU - Stauffer Larsen, Thomas

AU - Iversen, Katrine F

AU - Hansen, Esben

AU - Mathiasen, Anders Bruun

AU - Marcher, Claus Werenberg

AU - Frederiksen, Mikael Brink

AU - Larsen, Herdis

AU - Helleberg, Inge

AU - Riley, Caroline Hasselbalch

AU - Bjerrum, Ole W

AU - Rønnov-Jessen, Dorthe

AU - Møller, Michael Boe

AU - de Stricker, Karin

AU - Vestergaard, Hanne

AU - Hasselbalch, Hans Carl

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2013/9

Y1 - 2013/9

N2 - Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤ 2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.

AB - Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in the largest cohort of JAK2 V617F mutant MPN Danish patients (n=102) being treated long-term with rIFN-alpha2 (rIFN-alpha2a and rIFN-alpha2b in a non-clinical trial setting. The median follow-up was 42 months. We substantiate the capacity of rIFN-alpha2 to induce complete hematologic remissions (ET 95%, PV 68%) and molecular response. In total 76 patients (74.5%) had a decline in JAK2 V617F allele burden with a median reduction from baseline of 59% (95% c.i. 50-73%, range 3-99%). A decline in JAK2 V617F allele burden was recorded in both ET (median 24-10% (95% c.i.: 8-16%), and PV (median 59-35% (95% c.i.: 17-33%). Patients with the lowest pre-treatment JAK2 V617F allele burdens tend to achieve the most favourable responses on long term treatment with rIFN-alpha2. Eleven patients (10%) had deep molecular remissions with ≤ 2% JAK2 V617F mutant DNA. Finally, long term treatment with rIFN-alpha2 was associated with a very low thrombosis rate. Our observations are supportive of the concept of early up-front treatment with rIFN-alpha2.

KW - Adolescent

KW - Adult

KW - Aged

KW - Denmark

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Interferon-alpha

KW - Janus Kinase 2

KW - Male

KW - Middle Aged

KW - Mutation

KW - Polycythemia Vera

KW - Primary Myelofibrosis

KW - Prognosis

KW - Recombinant Proteins

KW - Remission Induction

KW - Retrospective Studies

KW - Thrombocythemia, Essential

KW - Time Factors

KW - Young Adult

U2 - 10.1016/j.leukres.2013.06.012

DO - 10.1016/j.leukres.2013.06.012

M3 - Journal article

VL - 37

SP - 1041

EP - 1045

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -

ID: 42570227